Conduct National Population-based HIV Impact Assessment (PHIA) in Nigeria under the President's Emergency Plan for AIDS Relief (PEPFAR)

The summary for the Conduct National Population-based HIV Impact Assessment (PHIA) in Nigeria under the President's Emergency Plan for AIDS Relief (PEPFAR) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Centers for Disease Control CGH, which is the U.S. government agency offering this grant.

Conduct National Population-based HIV Impact Assessment (PHIA) in Nigeria under the President's Emergency Plan for AIDS Relief (PEPFAR): This NOFO is to conduct a national PHIA in Nigeria, on behalf of the Government of Nigeria (GoN), to strengthen monitoring of program impact and outcomes to more comprehensively inform national responses to HIV. A PHIA is a large, nationally representative household survey used to collect data on the uptake of care and treatment services for HIV, provide home-based HIV counseling and testing, and estimate HIV incidence, CD4 T-cell counts, viral load, and HIV drug resistance. The Nigeria Population-based HIV Impact Assessment (NPHIA) will cover a representative sample of all the 36 states and the Federal Capital Territory (FCT) and will provide useful and actionable data that will increase cost efficiency and effectiveness of HIV programs. The data will assess the impact of PEPFAR and other stakeholder investment in ending Nigeria’s HIV epidemic and Nigeria’s progress towards achieving the Joint United Nations Program on HIV/AIDS (UNAIDS)/PEPFAR goal of testing 90 percent of people living with HIV (PLHIV), placing 90 percent of those on treatment, and achieving viral suppression in 90 percent of those on treatment.